Navigate

Star Equity Holdings, Inc. Announces 2023 First Quarter Financial Results

Consolidated Gross Profit increased 63% in Q1 2023 versus Q1 2022

Reports Net Income of $0.4 million and Non-GAAP Adjusted Net Income of $0.9 million

Adjusted EBITDA of $1.7 million in Q1 2023 versus $0.1 million in Q1 2022

OLD GREENWICH, Conn., May 15, 2023 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star Equity” or the “Company”), a diversified holding company, reported today its financial results for the first quarter (Q1) ended March 31, 2023. All 2023 and 2022 amounts in this release are unaudited.

Q1 Quarter 2023 Financial Highlights vs. Q1 Quarter 2022 (unaudited)

  • Revenues increased by 2.6% to $25.7 million from $25.0 million.
  • Gross profit increased by 62.8% to $7.6 million from $4.7 million.
  • Net income was $0.4 million (or $0.03 per basic and diluted share) compared to a net loss of $3.7 million (or $0.29 per basic and diluted share).
  • Non-GAAP adjusted net income was $0.9 million (or $0.06 per diluted share) compared to a loss of $0.7 million (or $0.05 per diluted share).
  • Non-GAAP adjusted EBITDA was $1.7 million versus $0.1 million.
  • As of March 31, 2023, cash and cash equivalents of $5.7 million decreased compared to cash and cash equivalents of $15.0 million at March 31, 2022; net debt, defined as total debt less total cash and cash equivalents, increased to net debt of $2.7 million from net cash of $1.7 million.

Rick Coleman, Chief Executive Officer, noted, “Star Equity’s strong start to 2023 reflects the team’s continued execution on our operating plan. We achieved first quarter adjusted EBITDA of $1.7 million, versus $0.1 million in the first quarter of last year, primarily due to continued strong top and bottom-line growth at our Construction division. Better operational efficiency, pricing, and cost discipline drove the Construction division’s improved results. Although Healthcare division revenue was roughly flat versus the prior year quarter, gross margin improved by 1.2 percentage points to 24.9% due to our realigned focus on higher-margin products and services stemming from our May 2022 reorganization.”

Mr. Coleman continued, “With the sale of Digirad Health on May 4, we have significantly strengthened our balance sheet and are well positioned to execute on our growth strategy of generating organic growth at our Construction division, and completing acquisitions — which could either be Construction bolt-ons or entries into new business sectors — and thoughtfully expanding activity at our Investments division. We plan to provide shareholders updates on these and other initiatives over time.”

Revenues

The Company’s Q1 2023 revenues increased 2.6% to $25.7 million from $25.0 million in the first quarter of 2022.

Revenues in $ thousands  Q1 2023  Q1 2022  % change
Healthcare  $ 13,359   $ 13,418   (0.4)%
Construction   12,346    11,631   6.1 %
Investments   158    158   — %
Intersegment elimination   (158 )   (158 )  — %
Total Revenues  $ 25,705   $ 25,049   2.6 %

Healthcare revenue decreased 0.4% compared to the prior year quarter, which reflects a slightly different mix of business versus 2022. The increase in revenue for the Construction division was driven by improved performance at both our KBS and EBGL businesses.

Gross Profit

Gross profit (loss) in $ thousands  Q1 2023  Q1 2022  % change
Healthcare  $ 3,327   $ 3,176   4.8 %
Healthcare gross margin   24.9 %   23.7 %  1.2 %
Construction   4,329    1,586   173.0 %
Construction gross margin   35.1 %   13.6 %  21.5 %
Investments   95    59   61.0 %
Intersegment elimination   (158 )   (158 )  N/M
Total gross profit  $ 7,593   $ 4,663   62.8 %
Total gross margin   29.5 %   18.6 %  10.9 %

Healthcare gross profit increased 4.8% for the three months ended March 31, 2023, compared to the same period in the prior year and reflects a slightly different business mix versus 2022.

The 173.0% increase in Construction gross profit was predominately due to stronger pricing levels, lower input costs, and improved operating efficiency versus Q1 2022.

Operating Expenses

On a consolidated basis, Q1 2023 sales, general and administrative (“SG&A”) expenses decreased by $0.4 million, or 5.2%, versus the prior year period. The major driver of the decrease in SG&A was a $0.4 million decrease in audit and tax service expense. SG&A as a percentage of revenue decreased in Q1 2023 to 25.0% versus 27.1% in Q1 2022.

Net Income

Q1 2023 net income from continuing operations was $0.4 million, or $0.03 per basic and diluted share, compared to net loss of $3.7 million, or $0.29 per basic and diluted share in the same period in the prior year. Q1 2023 non-GAAP adjusted net income from continuing operations was $0.9 million, or $0.06 per diluted share, compared to non-GAAP adjusted net loss from continuing operations of $0.7 million, or $0.05 per diluted share, in the prior year period.

Non-GAAP Adjusted EBITDA

Q1 2023 non-GAAP adjusted EBITDA was $1.7 million versus of $0.1 million in the same quarter of the prior year due to improvements in the Company’s operations leading to increased gross profit at both our Healthcare and Construction divisions.

Operating Cash Flow

Q1 2023 cash flow from operations was an inflow of $5.1 million, compared to an outflow of $0.6 million for the same period in the prior year, primarily as a result of improved profitability at our operating businesses, particularly at our Construction Division, higher collections of accounts receivable, and lower SG&A expense.

Preferred Stock Dividends

In Q1 2023, the Company’s board of directors declared a cash dividend to holders of our Series A Preferred Stock of $0.25 per share, for an aggregate amount of approximately $0.5 million. The record date for this dividend was March 1, 2023, and the payment date was March 10, 2023. As of March 31, 2023, the Company had no preferred dividends in arrears.

Conference Call Information

A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on May 15, 2023 to discuss the results and management’s outlook. The call may be accessed by dialing (833) 630-1956 (toll free) or (412) 317-1837 (international), five minutes prior to the scheduled start time and referencing Star Equity. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at www.starequity.com/events-and-presentations/presentations; an archived replay of the webcast will be available within 15 minutes of the end of the conference call.

If you have any questions, either prior to or after our scheduled Earnings Conference call, please e-mail admin@starequity.com or lcati@equityny.com. 

Use of Non-GAAP Financial Measures by Star Equity Holdings, Inc.

This release presents the non-GAAP financial measures “adjusted net income (loss),” “adjusted net income (loss) per basic and diluted share,” and “adjusted EBITDA from continuing operations.” The most directly comparable measures for these non-GAAP financial measures are “net income (loss),” “net income (loss) per basic and diluted share,” and “cash flows from operating activities.” The Company has included below unaudited adjusted financial information, which presents the Company’s results of operations after excluding acquired intangible asset amortization, unrealized gain (loss) on equity securities and lumber derivatives, litigation costs, financing costs, and income tax adjustments. Further excluded in the measure of adjusted EBITDA are stock-based compensation, interest, depreciation, and amortization.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s report on Form 8-K filed with the Securities and Exchange Commission on May 15, 2023.

About Star Equity Holdings, Inc.

Star Equity Holdings, Inc. is a diversified holding company with two divisions: Construction and Investments. Prior to the May 4, 2023 sale of Digirad Health, Star Equity Holdings had three divisions: Healthcare, Construction and Investments.

Healthcare

Our Healthcare division, which operated as Digirad Health until the sale of Digirad Health on May 4, 2023, provided products and services in the area of nuclear medical imaging with a focus on cardiac health. Digirad Health operated across the United States and comprises two lines of business—imaging services offered to healthcare providers using a fleet of our proprietary solid-state gamma cameras and the manufacturing, distribution, and maintenance of our proprietary solid-state gamma cameras.

Construction

Our Construction division manufactures modular housing units for commercial and residential real estate projects and operates in two businesses: (i) modular building manufacturing and (ii) structural wall panel and wood foundation manufacturing, including building supply distribution operations for professional builders.

Investments

Our Investments division manages and finances the Company’s real estate assets as well as its investment positions in private and public companies.

Forward-Looking Statements

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this release that are not statements of historical fact are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking Statements include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to acquisitions and related integration, development of commercially viable products, novel technologies, and modern applicable services, (ii) projections of income (including income/loss), EBITDA, earnings (including earnings/loss) per share, capital expenditures, cost reductions, capital structure or other financial items, (iii) the future financial performance of the Company or acquisition targets and (iv) the assumptions underlying or relating to any statement described above. Moreover, forward-looking statements necessarily involve assumptions on the Company’s part. These forward-looking statements generally are identified by the words “believe”, “expect”, “anticipate”, “estimate”, “project”, “intend”, “plan”, “should”, “may”, “will”, “would”, “will be”, “will continue” or similar expressions. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described above as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the substantial amount of debt of the Company and the Company’s ability to repay or refinance it or incur additional debt in the future; the Company’s need for a significant amount of cash to service and repay the debt and to pay dividends on the Company’s preferred stock; the restrictions contained in the debt agreements that limit the discretion of management in operating the business; legal, regulatory, political and economic risks in markets and public health crises that reduce economic activity and cause restrictions on operations (including the recent coronavirus COVID-19 outbreak); the length of time associated with servicing customers; losses of significant contracts or failure to get potential contracts being discussed; disruptions in the relationship with third party vendors; accounts receivable turnover; insufficient cash flows and resulting lack of liquidity; the Company’s inability to expand the Company’s business; unfavorable changes in the extensive governmental legislation and regulations governing healthcare providers and the provision of healthcare services and the competitive impact of such changes (including unfavorable changes to reimbursement policies); high costs of regulatory compliance; the liability and compliance costs regarding environmental regulations; the underlying condition of the technology support industry; the lack of product diversification; development and introduction of new technologies and intense competition in the healthcare industry; existing or increased competition; risks to the price and volatility of the Company’s common stock and preferred stock; stock volatility and in liquidity; risks to preferred stockholders of not receiving dividends and risks to the Company’s ability to pursue growth opportunities if the Company continues to pay dividends according to the terms of the Company’s preferred stock; the Company’s ability to execute on its business strategy (including any cost reduction plans); the Company’s failure to realize expected benefits of restructuring and cost-cutting actions; the Company’s ability to preserve and monetize its net operating losses; risks associated with the Company’s possible pursuit of acquisitions; the Company’s ability to consummate successful acquisitions and execute related integration, as well as factors related to the Company’s business including economic and financial market conditions generally and economic conditions in the Company’s markets; failure to keep pace with evolving technologies and difficulties integrating technologies; system failures; losses of key management personnel and the inability to attract and retain highly qualified management and personnel in the future; and the continued demand for and market acceptance of the Company’s services. For a detailed discussion of cautionary statements and risks that may affect the Company’s future results of operations and financial results, please refer to the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the risk factors in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. This release reflects management’s views as of the date presented.

All forward-looking statements are necessarily only estimates of future results, and there can be no assurance that actual results will not differ materially from expectations, and, therefore, you are cautioned not to place undue reliance on such statements. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events.

For more information contact: Â
Star Equity Holdings, Inc. The Equity Group
Rick Coleman Lena Cati
Chief Executive Officer Senior Vice President
203-489-9508 212-836-9611
rick.coleman@starequity.com lcati@equityny.comÂ

(Financial tables follow)

Star Equity Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited) (In thousands, except for per share amounts)
Â
  Three Months Ended March 31,
   2023    2022 Â
Revenues: Â Â Â Â
Healthcare  $ 13,359   $ 13,418 Â
Construction   12,346    11,631 Â
Total revenues   25,705    25,049 Â
    Â
Cost of revenues: Â Â Â Â
Healthcare   10,032    10,242 Â
Construction   8,017    10,045 Â
Investments   63    99 Â
Total cost of revenues   18,112    20,386 Â
    Â
Gross profit   7,593    4,663 Â
    Â
Operating expenses: Â Â Â Â
Selling, general and administrative   6,433    6,788 Â
Amortization of intangible assets   430    430 Â
Total operating expenses   6,863    7,218 Â
    Â
Income (loss) from operations   730    (2,555 )
    Â
Other income (expense): Â Â Â Â
Other income (expense), net   (100 )   (6 )
Interest expense, net   (195 )   (190 )
Total other income (expense), net   (295 )   (196 )
    Â
Income (loss) before income taxes   435    (2,751 )
Income tax benefit (provision)   —    (950 )
Net income (loss) Â Â 435 Â Â Â (3,701 )
Deemed dividend on Series A perpetual preferred stock   (479 )   (479 )
Net income (loss) attributable to common shareholders  $ (44 )  $ (4,180 )
    Â
Net income (loss) per share    Â
Basic* Â $ 0.03 Â Â $ (0.29 )
Diluted* Â $ 0.03 Â Â $ (0.29 )
Net income (loss) per share, attributable to common shareholders    Â
Basic*  $ —   $ (0.33 )
Diluted*  $ —   $ (0.33 )
Weighted-average common shares outstanding    Â
Basic* Â Â 15,516 Â Â Â 12,669 Â
Diluted* Â Â 15,656 Â Â Â 12,669 Â
    Â
Dividends declared per share of Series A perpetual preferred stock  $ 0.25   $ 0.25 Â

*Earnings per share may not add due to rounding

Star Equity Holdings, Inc.
Condensed Consolidated Balance Sheets
(Unaudited) (In thousands, except share amounts)
Â
 March 31, 2023
(unaudited) 		Â December 31,
2022
Assets: Â Â Â
Current assets: Â Â Â
Cash and cash equivalents $ 5,655 Â Â $ 4,665 Â
Restricted cash  141    142 Â
Investments in equity securities  3,577    3,490 Â
Accounts receivable, net of allowances of $500 and $714, respectively  15,000    17,756 Â
Inventories, net  10,043    10,627 Â
Other current assets  2,239    2,587 Â
Total current assets  36,655    39,267 Â
Property and equipment, net  8,102    8,348 Â
Operating lease right-of-use assets, net  4,040    4,482 Â
Intangible assets, net  12,922    13,352 Â
Goodwill  6,046    6,046 Â
Other assets  1,736    1,807 Â
Total assets $ 69,501 Â Â $ 73,302 Â
   Â
Liabilities and Stockholders’ Equity:   Â
Current liabilities: Â Â Â
Accounts payable $ 4,125 Â Â $ 3,430 Â
Accrued liabilities  2,665    3,137 Â
Accrued compensation  4,025    3,701 Â
Accrued warranty  290    291 Â
Lumber derivative contracts  62    104 Â
Deferred revenue  2,926    3,376 Â
Short-term debt  8,394    11,682 Â
Operating lease liabilities  1,371    1,427 Â
Finance lease liabilities  348    397 Â
Total current liabilities  24,206    27,545 Â
Deferred tax liabilities  176    176 Â
Operating lease liabilities, net of current portion  2,749    3,141 Â
Finance lease liabilities, net of current portion  300    386 Â
Deferred Revenue, net of current portion  257    299 Â
Total liabilities  27,688    31,547 Â
   Â
Stockholders’ Equity:   Â
Series A Preferred stock, $0.0001 par value: 10,000,000 shares authorized: 8,000,000 shares authorized, liquidation preference ($10.00 per share), 1,915,637 shares issued and outstanding at March 31, 2023. (Liquidation preference: $18,988,390 as of March 31, 2023.)  18,988    18,988 Â
Series C Preferred stock, $0.0001 par value: 25,000 shares authorized; no shares issued or outstanding  —    — Â
Common stock, $0.0001 par value: 50,000,000 shares authorized, respectively; 15,192,753 and 15,177,919 shares issued and outstanding (net of treasury shares) at March 31, 2023 and December 31, 2022, respectively  1    1 Â
Treasury stock, at cost; 258,849 shares at March 31, 2023 and December 31, 2022, respectively  (5,728 )   (5,728 )
Additional paid-in capital  161,338    161,715 Â
Accumulated deficit  (132,786 )   (133,221 )
Total stockholders’ equity  41,813    41,755 Â
Total liabilities and stockholders’ equity $ 69,501   $ 73,302 Â

Star Equity Holdings, Inc.
Reconciliation of Non-GAAP Financial Measures
(Unaudited) (In thousands, except per share amounts)
Â
  Three Months Ended March 31,
   2023    2022 Â
Net income (loss) Â $ 435 Â Â $ (3,701 )
Acquired intangible amortization   430    430 Â
Unrealized loss (gain) on equity securities(1)   (2 )   — Â
Unrealized loss (gain) on lumber derivatives(2) Â Â (43 ) Â Â 676 Â
Litigation costs(3) Â Â 22 Â Â Â 868 Â
Financing costs(4) Â Â 100 Â Â Â 100 Â
Income tax (benefit) provision   —    950 Â
Non-GAAP adjusted net income (loss) Â $ 942 Â Â $ (677 )
    Â
Net income (loss) per diluted share   0.03    (0.29 )
Acquired intangible amortization   0.03    0.03 Â
Unrealized loss (gain) on equity securities(1)   —    — Â
Unrealized loss (gain) on lumber derivatives(2)   —    0.05 Â
Litigation costs(3)   —    0.07 Â
Financing costs(4) Â Â 0.01 Â Â Â 0.01 Â
Income tax (benefit) provision   —    0.07 Â
Non-GAAP adjusted net income (loss) per basic share(5) Â $ 0.06 Â Â $ (0.05 )
Non-GAAP adjusted net income (loss) per diluted share(5) Â $ 0.06 Â Â $ (0.05 )

(1)   Reflects adjustments for any unrealized gains or losses in equity securities.
(2)   Reflects adjustments for any unrealized gains or losses in lumber derivatives value.
(3)   Reflects one time litigation costs.
(4)   Reflects financing costs from our credit facilities.
(5)   Per share amounts are computed independently for each discrete item presented. Therefore, the sum of the quarterly per share amounts will not necessarily equal to the total for the year, and the sum of individual items may not equal the total.

Star Equity Holdings, Inc.
Reconciliation of Non-GAAP Financial Measures
(Unaudited) (In thousands)
Â
For The Three Months Ended March 31, 2023  Healthcare  Construction  Investments  Star Equity
Corporate		 Â Total
          Â
Net income (loss) Â $ 419 Â $ 1,654 Â Â $ (51 ) Â $ (1,587 ) Â $ 435 Â
Depreciation and amortization   272   505    63    4    844 Â
Interest (income) expense   168   29    22    (24 )   195 Â
Income tax (benefit) provision   —   —    —    —    — Â
EBITDA Â Â 859 Â Â 2,188 Â Â Â 34 Â Â Â (1,607 ) Â Â 1,474 Â
          Â
Unrealized loss (gain) on equity securities(1)   —   —    (2 )   —    (2 )
Unrealized loss (gain) on lumber derivatives(2)   —   (43 )   —    —    (43 )
Litigation costs(3)   22   —    —    —    22 Â
Stock-based compensation   1   5    —    96    102 Â
Financing costs(4)   5   84    11    —    100 Â
Non-GAAP adjusted EBITDA Â $ 887 Â $ 2,234 Â Â $ 43 Â Â $ (1,511 ) Â $ 1,653 Â

For The Three Months Ended March 31, 2022  Healthcare  Construction  Investments  Star Equity
Corporate		 Â Total
          Â
Net income (loss) Â $ (940 ) Â $ (916 ) Â $ 88 Â $ (1,933 ) Â $ (3,701 )
Depreciation and amortization   315    487    99   —    901 Â
Interest expense   64    79    47   —    190 Â
Income tax (benefit) provision   950    —    —   —    950 Â
EBITDA Â Â 389 Â Â Â (350 ) Â Â 234 Â Â (1,933 ) Â Â (1,660 )
          Â
Unrealized loss (gain) on lumber derivatives(2)   —    676    —   —    676 Â
Litigation costs(3)   868    —    —   —    868 Â
Stock-based compensation   15    6    —   123    144 Â
Financing costs(4)   5    78    17   —    100 Â
Non-GAAP adjusted EBITDA Â $ 1,277 Â Â $ 410 Â Â $ 251 Â $ (1,810 ) Â $ 128 Â

(1)   Reflects adjustments for any unrealized gains or losses on equity securities.
(2)   Reflects adjustments for any unrealized gains or losses in lumber derivatives value.
(3)   Reflects one time litigation costs.
(4)   Reflects financing costs from our credit facilities.

Star Equity Holdings, Inc.
Supplemental Debt Information
(Unaudited) (In thousands)
Â
A summary of the Company’s credit facilities are as follows:
  March 31, 2023  December 31, 2022
  Amount  Weighted-
Average
Interest Rate		  Amount  Weighted-
Average
Interest Rate
Revolving Credit Facility – eCapital KBS  $ —  10.75 %  $ —  10.25 %
Revolving Credit Facility – eCapital EBGL   —  10.75 %   2,592  10.25 %
Revolving Credit Facility – Webster   7,685  7.36 %   8,299  6.89 %
Total Short-term Revolving Credit Facilities  $ 7,685  7.36 %  $ 10,891  7.69 %
eCapital – Star Loan Principal, net  $ 709  11.00 %  $ 791  10.50 %
Short Term Loan  $ 709  11.00 %  $ 791  10.50 %
Total Short-term debt  $ 8,394  7.67 %  $ 11,682  7.88 %

Star Equity Holdings, Inc.
Supplemental Segment Information
(Unaudited) (In thousands)
Â
  Three Months Ended
March 31,
   2023    2022 Â
Revenue by segment: Â Â Â Â
Healthcare  $ 13,359   $ 13,418 Â
Construction   12,346    11,631 Â
Investments   158    158 Â
Intersegment elimination   (158 )   (158 )
Consolidated revenue  $ 25,705   $ 25,049 Â
    Â
Gross profit (loss) by segment: Â Â Â Â
Healthcare  $ 3,327   $ 3,176 Â
Construction   4,329    1,586 Â
Investments   95    59 Â
Intersegment elimination   (158 )   (158 )
Consolidated gross profit  $ 7,593   $ 4,663 Â
    Â
Income (loss) from continuing operations by segment: Â Â Â Â
Healthcare  $ 579   $ 78 Â
Construction   1,782    (759 )
Investments   (19 )   59 Â
Corporate, eliminations and other   (1,612 )   (1,933 )
Segment income (loss) from operations  $ 730   $ (2,555 )
    Â
Depreciation and amortization by segment: Â Â Â Â
Healthcare  $ 272   $ 315 Â
Construction   505    487 Â
Investments   63    99 Â
Star Equity corporate  $ 4   $ — Â
Total depreciation and amortization  $ 844   $ 901 Â

Alex:
Related Post
  1. Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
  2. JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
  3. Volume 3 APAC Flavours and Fragrances Market Overview 2022: Players Include IFF, Kerry, Mane SA, Robertet, Sensient and Symrise – ResearchAndMarkets.com

Search